GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Net Income

Sanara MedTech (Sanara MedTech) Net Income : $-4.30 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Sanara MedTech's Net Income for the three months ended in Dec. 2023 was $-0.24 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.30 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Sanara MedTech's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.03.


Sanara MedTech Net Income Historical Data

The historical data trend for Sanara MedTech's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Net Income Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.81 -4.36 -7.92 -7.94 -4.30

Sanara MedTech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.11 -1.18 -1.83 -1.06 -0.24

Sanara MedTech Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Sanara MedTech's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-4.44+0+0+0.137
=-4.30

Sanara MedTech's Net Income for the quarter that ended in Dec. 2023 is calculated as

Net Income(Q: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-0.262+0+0+0.025
=-0.24

Net Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sanara MedTech  (NAS:SMTI) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Sanara MedTech's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Sanara MedTech Net Income Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077